Συγγραφείς:
Vassilakopoulos, T.P.
Apostolidis, J.
Angelopoulou, M.K.
Λέξεις-κλειδιά:
rituximab; antineoplastic agent; rituximab, B cell lymphoma; bone marrow; clinical trial (topic); drug efficacy; event free survival; female; gender; human; large cell lymphoma; Letter; male; overall survival; unspecified side effect; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Male; Rituximab